Benzylacyclouridine	benzylacyclouridine	O	O	OTHERS	I
reverses	reverses	O	O	O	O
azidothymidine-induced	azidothymidine-induced	O	O	O	O
marrow	marrow	O	O	OTHERS	I
suppression	suppression	O	O	OTHERS	I
without	without	O	O	O	O
impairment	impairment	O	O	O	O
of	of	O	O	O	O
anti-human	anti-human	O	O	O	O
immunodeficiency	immunodeficiency	O	O	OTHERS	I
virus	virus	O	O	O	O
activity	activity	O	O	O	O
.	.	O	O	O	O

Increased	increased	O	O	O	O
extracellular	extracellular	O	O	O	O
concentrations	concentrations	O	O	O	O
of	of	O	O	O	O
uridine	uridine	O	O	OTHERS	I
(	(	O	O	O	O
Urd	urd	O	O	OTHERS	I
)	)	O	O	O	O
have	have	O	O	O	O
been	been	O	O	O	O
reported	reported	O	O	O	O
to	to	O	O	O	O
reduce	reduce	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
vitro	vitro	O	O	O	O
,	,	O	O	O	O
azidothymidine	azidothymidine	CHEMICALS	O	OTHERS	I
(AZT)-induced	(azt)-induced	O	O	O	O
inhibition	inhibition	O	O	O	O
of	of	O	O	O	O
human	human	O	O	O	O
granulocyte-macrophage	granulocyte-macrophage	O	O	O	O
progenitor	progenitor	O	O	O	O
cells	cells	O	O	O	O
without	without	O	O	O	O
impairment	impairment	O	O	O	O
of	of	O	O	O	O
its	its	O	O	O	O
antihuman	antihuman	O	O	O	O
immunodeficiency	immunodeficiency	O	O	OTHERS	I
virus	virus	O	O	O	O
(	(	O	O	O	O
HIV	hiv	O	O	O	O
)	)	O	O	O	O
activity	activity	O	O	O	O
.	.	O	O	O	O

Because	because	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
clinical	clinical	O	O	O	O
toxicities	toxicities	O	DISEASE	OTHERS	I
associated	associated	O	O	O	O
with	with	O	O	O	O
chronic	chronic	O	O	O	O
Urd	urd	O	O	OTHERS	I
administration	administration	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
ability	ability	O	O	O	O
of	of	O	O	O	O
benzylacyclouridine	benzylacyclouridine	O	O	OTHERS	I
(	(	O	O	O	O
BAU	bau	O	O	OTHERS	I
)	)	O	O	O	O
to	to	O	O	O	O
effect	effect	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
vivo	vivo	O	O	O	O
,	,	O	O	O	O
AZT-induced	azt-induced	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
and	and	O	O	O	O
leukopenia	leukopenia	O	DISEASE	OTHERS	I
was	was	O	O	O	O
assessed	assessed	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
agent	agent	O	O	O	O
inhibits	inhibits	O	O	O	O
Urd	urd	O	O	OTHERS	I
catabolism	catabolism	O	O	O	O
and	and	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
vivo	vivo	O	O	O	O
,	,	O	O	O	O
increases	increases	O	O	O	O
the	the	O	O	O	O
plasma	plasma	O	O	O	O
concentration	concentration	O	O	O	O
of	of	O	O	O	O
Urd	urd	O	O	OTHERS	I
in	in	O	O	O	O
a	a	O	O	O	O
dose-dependent	dose-dependent	O	O	O	O
manner	manner	O	O	O	O
,	,	O	O	O	O
without	without	O	O	O	O
Urd-related	urd-related	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
mice	mice	O	O	O	O
rendered	rendered	O	O	O	O
anemic	anemic	O	O	OTHERS	I
and	and	O	O	O	O
leukopenic	leukopenic	O	O	OTHERS	I
by	by	O	O	O	O
the	the	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
AZT	azt	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
28	28	O	O	O	O
days	days	O	O	O	O
in	in	O	O	O	O
drinking	drinking	CHEMICALS	O	OTHERS	I
water	water	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
1.5	1.5	O	O	O	O
mg/mL	mg/ml	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
continued	continued	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
AZT	azt	CHEMICALS	O	OTHERS	I
plus	plus	O	O	O	O
daily	daily	O	O	O	O
BAU	bau	O	O	OTHERS	I
(	(	O	O	O	O
300	300	O	O	O	O
mg/kg	mg/kg	O	O	O	O
,	,	O	O	O	O
orally	orally	O	O	O	O
)	)	O	O	O	O
partially	partially	O	O	O	O
reversed	reversed	O	O	O	O
AZT-induced	azt-induced	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
and	and	O	O	O	O
leukopenia	leukopenia	O	DISEASE	OTHERS	I
(	(	O	O	O	O
P	p	O	O	OTHERS	I
less	less	O	O	O	O
than	than	O	O	O	O
.05	.05	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
increased	increased	O	O	O	O
peripheral	peripheral	O	O	O	O
reticulocytes	reticulocytes	O	O	O	O
(	(	O	O	O	O
to	to	O	O	O	O
4.9	4.9	O	O	O	O
%	%	O	O	O	O
,	,	O	O	O	O
P	p	O	O	OTHERS	I
less	less	O	O	O	O
than	than	O	O	O	O
.01	.01	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
increased	increased	O	O	O	O
cellularity	cellularity	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
marrow	marrow	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
improved	improved	O	O	O	O
megaloblastosis	megaloblastosis	O	O	OTHERS	I
.	.	O	O	O	O

When	when	O	O	O	O
coadministered	coadministered	O	O	O	O
with	with	O	O	O	O
AZT	azt	CHEMICALS	O	OTHERS	I
from	from	O	O	O	O
the	the	O	O	O	O
onset	onset	O	O	O	O
of	of	O	O	O	O
drug	drug	O	O	O	O
administration	administration	O	O	O	O
,	,	O	O	O	O
BAU	bau	O	O	OTHERS	I
reduced	reduced	O	O	O	O
AZT-induced	azt-induced	O	O	O	O
marrow	marrow	O	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
vitro	vitro	O	O	O	O
,	,	O	O	O	O
at	at	O	O	O	O
a	a	O	O	O	O
concentration	concentration	O	O	O	O
of	of	O	O	O	O
100	100	O	O	O	O
mumol/L	mumol/l	O	O	O	O
,	,	O	O	O	O
BAU	bau	O	O	OTHERS	I
possesses	possesses	O	O	O	O
minimal	minimal	O	O	O	O
anti-HIV	anti-hiv	O	O	O	O
activity	activity	O	O	O	O
and	and	O	O	O	O
has	has	O	O	O	O
no	no	O	O	O	O
effect	effect	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
ability	ability	O	O	O	O
of	of	O	O	O	O
AZT	azt	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
reverse	reverse	O	O	O	O
the	the	O	O	O	O
HIV-induced	hiv-induced	O	O	O	O
cytopathic	cytopathic	O	O	O	O
effect	effect	O	O	O	O
in	in	O	O	O	O
MT4	mt4	O	O	O	O
cells	cells	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
clinical	clinical	O	O	O	O
and	and	O	O	O	O
biochemical	biochemical	O	O	O	O
implications	implications	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
findings	findings	O	O	O	O
are	are	O	O	O	O
discussed	discussed	O	O	O	O
.	.	O	O	O	O

